1439 related articles for article (PubMed ID: 30178600)
1. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
2. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
[TBL] [Abstract][Full Text] [Related]
3. Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Sagara M; Niitani T; Kato K; Iijima T; Tomaru T; Jojima T; Usui I
J Investig Med; 2021 Oct; 69(7):1324-1329. PubMed ID: 34016738
[TBL] [Abstract][Full Text] [Related]
4. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
7. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
8. Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes.
Mak JHC; Lui DT; Fong CH; Cheung CY; Wong Y; Lee AC; Hoo RL; Xu A; Tan KC; Lam KS; Lee CH
Clin Endocrinol (Oxf); 2024 Mar; 100(3):230-237. PubMed ID: 38127469
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
[TBL] [Abstract][Full Text] [Related]
10. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
[TBL] [Abstract][Full Text] [Related]
11. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Shinozaki S; Tahara T; Lefor AK; Ogura M
J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
[TBL] [Abstract][Full Text] [Related]
12. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
[TBL] [Abstract][Full Text] [Related]
13. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
[TBL] [Abstract][Full Text] [Related]
15. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
[TBL] [Abstract][Full Text] [Related]
16. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial.
Leite NC; Viegas BB; Villela-Nogueira CA; Carlos FO; Cardoso CRL; Salles GF
Diabetes Obes Metab; 2019 May; 21(5):1266-1270. PubMed ID: 30687994
[TBL] [Abstract][Full Text] [Related]
18. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
[TBL] [Abstract][Full Text] [Related]
19. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shi M; Zhang H; Wang W; Zhang X; Liu J; Wang Q; Wang Y; Zhang C; Guo X; Qiao Q; Cui C; Xu J; Wang J
J Diabetes Complications; 2023 Oct; 37(10):108610. PubMed ID: 37722211
[TBL] [Abstract][Full Text] [Related]
20. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Phrueksotsai S; Pinyopornpanish K; Euathrongchit J; Leerapun A; Phrommintikul A; Buranapin S; Chattipakorn N; Thongsawat S
J Gastroenterol Hepatol; 2021 Oct; 36(10):2952-2959. PubMed ID: 34129252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
